Eukaryotic translation initiation factor 5A inhibition alters physiopathology and immune responses in a "humanized" transgenic mouse model of type 1 diabetes.
Therapeutic options for treatment of type 1 diabetes (T1D) are still missing. New avenues for immune modulation need to be developed. Here we attempted at altering the diabetes outcome of our humanized model of T1D by inhibiting translation-initiation factor eIF5A hypusination in vivo. Double-transgenic (DQ8-GAD65) mice were immunized with adenoviral vectors carrying GAD65 for diabetes induction. Animals were subsequently treated with deoxyhypusine synthase (DHS) inhibitor GC7 and monitored for diabetes development over time. On one hand, helper CD4(+) T cells were clearly affected by the downregulation of the eIF5A not just at the pancreas level but overall. On the other hand, the T regulatory cell component of CD4 responded with activation and proliferation significantly higher than in the non-GC7-treated controls. Female mice seemed to be more susceptible to these effects. All together, our results show for the first time that downregulation of eIF5A through inhibition of DHS altered the physiopathology and observed immune outcome of diabetes in an animal model that closely resembles human T1D. Although the development of diabetes could not be abrogated by DHS inhibition, the immunomodulatory capacity of this approach may supplement other interventions directed at increasing regulation of autoreactive T cells in T1D.
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin;
Shahnawaz
S
Imam
Raghavendra G
RG
Mirmira
Juan C
JC
Jaume
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005968:Glutamate Decarboxylase / Q000235:genetics / Q000276:immunology; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D059848:HLA-DQ alpha-Chains / Q000235:genetics / Q000276:immunology; D059866:HLA-DQ beta-Chains / Q000235:genetics / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects* / Q000235:genetics; D008239:Lysine / Q000031:analogs & derivatives / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000037:antagonists & inhibitors; D010448:Peptide Initiation Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000097574:Eukaryotic Translation Initiation Factor 5A
D004791:Enzyme Inhibitors; D005968:Glutamate Decarboxylase; D006147:Guanine; D059848:HLA-DQ alpha-Chains; D059866:HLA-DQ beta-Chains; D008239:Lysine; D000587:Oxidoreductases Acting on CH-NH Group Donors; D010448:Peptide Initiation Factors; D016601:RNA-Binding Proteins; D000097574:Eukaryotic Translation Initiation Factor 5A; C069050:HLA-DQA1 antigen; C069051:HLA-DQB1 antigen; C100667:N(1)-guanyl-1,7-diaminoheptane; C034924:deoxyhypusine; C063507:deoxyhypusine synthase; C401141:glutamate decarboxylase 2
deoxyhypusine synthase; mouse model; type 1 diabetes physiopathology